Q&A: Gilead pub­lic af­fairs chief on new strat­e­gy, Tik­Tok, and why the com­pa­ny won’t ‘keep do­ing things the same way’ 

Af­ter years of qui­et fo­cus on HIV and vi­rol­o­gy and sto­ic re­spons­es to flare-ups of at­ten­tion over its pric­ing de­ci­sions, the new Gilead Sci­ences is ready to talk.

It’s got a re­vamped pub­lic af­fairs strat­e­gy that fa­vors proac­tiv­i­ty and aims to own the com­pa­ny’s nar­ra­tive as it moves in­to on­col­o­gy and im­munol­o­gy.

Lead­ing the charge is Alex Kalom­par­is, se­nior VP of pub­lic af­fairs at Gilead. Now two years in­to the role, and sev­en to­tal years at Gilead, he wants to bet­ter tell the sto­ry of the bio­phar­ma’s ground­break­ing health eq­ui­ty work and then trans­late those lessons in­to how it com­mu­ni­cates in new ther­a­py ar­eas.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER